Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,otherCurrentAssets,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,changeToNetincome,capitalExpenditures,netBorrowings,otherCashflowsFromFinancingActivities,repurchaseOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,gmtOffSetMilliseconds,esgPopulated,tradeable,currency,marketState,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,shortName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchangeDataDelayedBy,exchange,priceHint,market,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,ICAD,44171000.0,24966300,2192000,,-1643000,,-1643000,5575000,6368000,-1533000,-1533000,,-112000,,,,0,8644000,10177000,2276000,-110000,,-1643000,-1643000,831000.0,298106000.0,22130000.0,53364000.0,6039000.0,75494000.0,251000.0,-243578000.0,424000.0,8362000.0,-1415000.0,1564000.0,46907000.0,14143000.0,269000.0,2495000.0,62242000.0,11350000.0,6703000.0,2498000.0,1251000.0,,-1624000.0,-262000.0,23546000.0,-1402000.0,23546000.0,19721000.0,-3563000.0,134000.0,647000.0,-622000.0,935000.0,-262000.0,,,,48099000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.9950239,11.665 - 12.2,12.06,0.0,0.0,9,8,finmb_279728,NasdaqCM,"iCAD, Inc.",USD,161256,142914,3.7000008,0.43632087,8.48 - 21.44,-9.26,-0.43190297,8.48,21.44,1619625661,1635969600,1636401600,-14400000,False,False,USD,PRE,-0.324,-0.04,-0.31,-39.290325,2.138,13.205428,-1.0254278,-0.07765199,16.604492,-4.424492,-0.26646355,304089536,-304.5,5.6969132,15,America/New_York,EDT,icad inc.,12.18,1630526403,0.119999886,12.11,12.2,11.665,116387,0,NCM,2,us_market,1.17,,,21.44,8.48,13.21,16.6,161.26k,142.91k,24.97M,,22.49M,7.58%,52.56%,807.86k,7.04,3.50%,3.24%,767.54k,,,,,,0.00%,,,1:5,"Aug 15, 2012","Dec 30, 2020","Mar 30, 2021",-23.41%,-22.11%,-7.75%,-21.74%,31.79M,1.38,31.90%,21.73M,-6.47M,-7.44M,-0.32,,46.91M,1.88,8.68M,16.26,4.40,2.14,-9.13M,-5.62M,Value,03062,Healthcare,113,7,8,"iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",Nashua,603 882 5200,NH,2,1609372800,1622505600,7,United States,http://www.icadmed.com,86400,5,98 Spit Brook Road,Health Information Services,Suite 100
t-1,ICAD,21274000.0,24966300,2176000,,-1599000,,-1603000,6735000,7554000,-1495000,-1495000,,-116000,,,,4000,10451000,11946000,2897000,-104000,,-1603000,-1603000,889000.0,273639000.0,25057000.0,30525000.0,6117000.0,55582000.0,236000.0,-241935000.0,271000.0,8362000.0,-1415000.0,1527000.0,27186000.0,16751000.0,,2502000.0,42302000.0,10508000.0,6960000.0,3144000.0,2869000.0,406000.0,1030000.0,-188000.0,5643000.0,656000.0,6482000.0,4553000.0,-902000.0,137000.0,2000.0,-1453000.0,316000.0,-186000.0,-775000.0,-64000.0,,25551000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.9950239,11.665 - 12.2,12.06,0.0,0.0,9,8,finmb_279728,NasdaqCM,"iCAD, Inc.",USD,161256,142914,3.7000008,0.43632087,8.48 - 21.44,-9.26,-0.43190297,8.48,21.44,1619625661,1635969600,1636401600,-14400000,False,False,USD,PRE,-0.324,-0.04,-0.31,-39.290325,2.138,13.205428,-1.0254278,-0.07765199,16.604492,-4.424492,-0.26646355,304089536,-304.5,5.6969132,15,America/New_York,EDT,icad inc.,12.18,1630526403,0.119999886,12.11,12.2,11.665,116387,0,NCM,2,us_market,1.17,,,21.44,8.48,13.21,16.6,161.26k,142.91k,24.97M,,22.49M,7.58%,52.56%,807.86k,7.04,3.50%,3.24%,767.54k,,,,,,0.00%,,,1:5,"Aug 15, 2012","Dec 30, 2020","Mar 30, 2021",-23.41%,-22.11%,-7.75%,-21.74%,31.79M,1.38,31.90%,21.73M,-6.47M,-7.44M,-0.32,,46.91M,1.88,8.68M,16.26,4.40,2.14,-9.13M,-5.62M,Value,03062,Healthcare,113,7,8,"iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",Nashua,603 882 5200,NH,2,1609372800,1622505600,7,United States,http://www.icadmed.com,86400,5,98 Spit Brook Road,Health Information Services,Suite 100
t-2,ICAD,16021000.0,24966300,1849000,,-1794000,,-1797000,4813000,5117000,-1689000,-1689000,,-115000,,,,3000,7129000,8818000,2012000,-105000,,-1797000,-1797000,962000.0,266861000.0,22462000.0,25345000.0,5702000.0,47807000.0,231000.0,-240332000.0,223000.0,8362000.0,-1415000.0,101000.0,22633000.0,14223000.0,994000.0,2565000.0,35817000.0,8383000.0,6729000.0,3146000.0,2084000.0,,1137000.0,-100000.0,1018000.0,-584000.0,409000.0,-1592000.0,-2510000.0,144000.0,202000.0,-2050000.0,426000.0,-95000.0,775000.0,59000.0,-225000.0,21594000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.9950239,11.665 - 12.2,12.06,0.0,0.0,9,8,finmb_279728,NasdaqCM,"iCAD, Inc.",USD,161256,142914,3.7000008,0.43632087,8.48 - 21.44,-9.26,-0.43190297,8.48,21.44,1619625661,1635969600,1636401600,-14400000,False,False,USD,PRE,-0.324,-0.04,-0.31,-39.290325,2.138,13.205428,-1.0254278,-0.07765199,16.604492,-4.424492,-0.26646355,304089536,-304.5,5.6969132,15,America/New_York,EDT,icad inc.,12.18,1630526403,0.119999886,12.11,12.2,11.665,116387,0,NCM,2,us_market,1.17,,,21.44,8.48,13.21,16.6,161.26k,142.91k,24.97M,,22.49M,7.58%,52.56%,807.86k,7.04,3.50%,3.24%,767.54k,,,,,,0.00%,,,1:5,"Aug 15, 2012","Dec 30, 2020","Mar 30, 2021",-23.41%,-22.11%,-7.75%,-21.74%,31.79M,1.38,31.90%,21.73M,-6.47M,-7.44M,-0.32,,46.91M,1.88,8.68M,16.26,4.40,2.14,-9.13M,-5.62M,Value,03062,Healthcare,113,7,8,"iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",Nashua,603 882 5200,NH,2,1609372800,1622505600,7,United States,http://www.icadmed.com,86400,5,98 Spit Brook Road,Health Information Services,Suite 100
t-3,ICAD,17093000.0,24966300,1878000,,-2393000,,-2398000,4741000,4455000,-2311000,-2311000,,-115000,,,,5000,5567000,7878000,1112000,-82000,,-2398000,-2398000,1037000.0,266211000.0,21421000.0,26492000.0,5560000.0,47913000.0,231000.0,-238535000.0,202000.0,8362000.0,-1415000.0,110000.0,24225000.0,12785000.0,,2721000.0,35683000.0,6679000.0,6937000.0,3348000.0,1421000.0,,-79000.0,-30000.0,12156000.0,-1158000.0,12193000.0,9969000.0,-2157000.0,147000.0,-886000.0,591000.0,1613000.0,-25000.0,-43000.0,6000.0,-225000.0,22898000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.9950239,11.665 - 12.2,12.06,0.0,0.0,9,8,finmb_279728,NasdaqCM,"iCAD, Inc.",USD,161256,142914,3.7000008,0.43632087,8.48 - 21.44,-9.26,-0.43190297,8.48,21.44,1619625661,1635969600,1636401600,-14400000,False,False,USD,PRE,-0.324,-0.04,-0.31,-39.290325,2.138,13.205428,-1.0254278,-0.07765199,16.604492,-4.424492,-0.26646355,304089536,-304.5,5.6969132,15,America/New_York,EDT,icad inc.,12.18,1630526403,0.119999886,12.11,12.2,11.665,116387,0,NCM,2,us_market,1.17,,,21.44,8.48,13.21,16.6,161.26k,142.91k,24.97M,,22.49M,7.58%,52.56%,807.86k,7.04,3.50%,3.24%,767.54k,,,,,,0.00%,,,1:5,"Aug 15, 2012","Dec 30, 2020","Mar 30, 2021",-23.41%,-22.11%,-7.75%,-21.74%,31.79M,1.38,31.90%,21.73M,-6.47M,-7.44M,-0.32,,46.91M,1.88,8.68M,16.26,4.40,2.14,-9.13M,-5.62M,Value,03062,Healthcare,113,7,8,"iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.",Nashua,603 882 5200,NH,2,1609372800,1622505600,7,United States,http://www.icadmed.com,86400,5,98 Spit Brook Road,Health Information Services,Suite 100
